Cytarabine and Acute bilateral obstructive uropathy - a phase IV clinical study of FDA data

Summary:

Acute bilateral obstructive uropathy is reported as a side effect among people who take Cytarabine (cytarabine), especially for people who are male, 60+ old, also take Cyclophosphamide, and have Mantle cell lymphoma stage iv.

The phase IV clinical study analyzes which people have Acute bilateral obstructive uropathy when taking Cytarabine. It is created by eHealthMe based on reports of 65,319 people who have side effects when taking Cytarabine from the FDA, and is updated regularly.

What is Cytarabine?

Cytarabine has active ingredients of cytarabine. It is often used in acute myelogenous leukemia (aml) - adult. eHealthMe is studying from 65,358 Cytarabine users. Check the latest studies of Cytarabine.

What is Acute bilateral obstructive uropathy?

Acute bilateral obstructive uropathy (sudden blockage of the flow of urine from both kidneys) is found to be associated with 130 drugs and 408 conditions by eHealthMe. Check the latest studies of Acute bilateral obstructive uropathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

65,319 people reported to have side effects when taking Cytarabine.
Among them, 12 people (0.02%) have Acute bilateral obstructive uropathy.

Could Cytarabine cause Acute bilateral obstructive uropathy?

Among these 12 people:

What is the gender of people who have Acute bilateral obstructive uropathy when taking Cytarabine? *

female: 0.0 %
male: 100 %

What is the age of people who have Acute bilateral obstructive uropathy when taking Cytarabine? *

What are other drugs people take besides Cytarabine? *

Prednisolone: 12 people, 100.00%
Cyclophosphamide: 12 people, 100.00%
Bendamustine Hydrochloride: 8 people, 66.67%
Bendamustine: 4 people, 33.33%
Doxorubicin Hydrochloride: 1 person, 8.33%

What are other side effects people have besides Acute bilateral obstructive uropathy? *

Unilateral Hydronephrosis (kidney stone that causes obstruction of the ureter): 12 people, 100.00%
Pathogen Resistance: 12 people, 100.00%
Back Pain: 12 people, 100.00%
Cardiac Failure: 12 people, 100.00%
Nodule (a growth of abnormal tissue): 12 people, 100.00%
Neuroendocrine Carcinoma Of The Skin (a rare type of cancer that forms on or just beneath the skin, usually in parts of the body that have been exposed to the sun): 12 people, 100.00%
Pneumonia: 12 people, 100.00%
Pneumonia Pseudomonal (pseudomonas pneumonia is an infection caused by the microbe known as pseudomonas aeruginosa): 12 people, 100.00%
Scrotal Oedema (swelling of scrotum): 12 people, 100.00%
Aplasia (defective development or congenital absence of an organ or tissue): 11 people, 91.67%

What are the existing conditions these people have? *

Mantle Cell Lymphoma Stage Iv (cancer of lymphocytes, a type of white blood cell, spreads to other part of body): 12 people, 100.00%
Malignant Neoplasm Progression (cancer tumour came back): 7 people, 58.33%
Disease Progression: 5 people, 41.67%

* Approximation only. Some reports may have incomplete information.

Do you take Cytarabine and have Acute bilateral obstructive uropathy?

- Check whether Acute bilateral obstructive uropathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cytarabine:

Cytarabine (65,358 reports)

Browse all side effects of Cytarabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Acute bilateral obstructive uropathy:

Acute bilateral obstructive uropathy (130 drugs)

Browse all the conditions that are associated with Acute bilateral obstructive uropathy:

Acute bilateral obstructive uropathy (408 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cytarabine (the active ingredients of Cytarabine) and Cytarabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.